FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897943350> ?p ?o ?g. }

• W2897943350 endingPage "542" @default.
• W2897943350 startingPage "537" @default.
• W2897943350 abstract ": Malignant peritoneal mesothelioma (MPM) is a very rare malignancy of the peritoneum and has a poor prognosis. Of all mesotheliomas, pleural mesothelioma is more common than MPM. In comparison to pleural mesothelioma, the link with asbestos exposure is weaker (33–50% vs. >80%), but it is still the best-defined risk factor. MPM spreads predominantly expansive rather than infiltrative and symptoms are related to tumor spread within the abdominal cavity. Often, MPM is encountered incidentally by diagnostic imaging or by surgery. Computed tomography scan is widely accepted as a first line modality in diagnostic imaging. In diagnostic histopathology, MPM presents some challenges. Firstly, adequate clinical information is of utmost importance to consider the possibility of the diagnosis of MPM. Furthermore, a few morphological subtypes and variants exist. The most sensitive immunohistochemical markers are calretinin (100%), WT1 (94%) and CK5/6 (89%). The malignant character of immunohistochemically demonstrated mesothelial cells is not always obvious. This paradigm somewhat changed with the advent of immunohistochemical demonstration of BAP1 (BRCA-1 associated protein 1). Loss of BAP1 expression supports a diagnosis of malignancy. The gold standard in treatment remains cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC). Targetable molecular pathways in MPM are being identified. An exciting finding was the demonstration of ALK rearrangements in a small subset of patients with MPM and it is hoped for that at least this small subgroup of patients could benefit from treatment with ALK inhibitors. First-generation tyrosine kinase inhibitors against epidermal growth factor receptor (EGFR) did not show any significant activity in MPM. In contrast, nintedanib, an angiokinase inhibitor, improved progression-free survival and bevacizumab, a humanized anti-VEGF antibody increased overall survival in patients with MPM, when administered in combination with cisplatin and pemetrexed. Ongoing immunotherapy trials will offer a possible new treatment." @default.
• W2897943350 created "2018-10-26" @default.
• W2897943350 creator A5048441847 @default.
• W2897943350 creator A5056727791 @default.
• W2897943350 date "2018-10-01" @default.
• W2897943350 modified "2023-10-14" @default.
• W2897943350 title "Malignant peritoneal mesothelioma: a review" @default.
• W2897943350 cites W17791541 @default.
• W2897943350 cites W1965686174 @default.
• W2897943350 cites W1988500296 @default.
• W2897943350 cites W2014415600 @default.
• W2897943350 cites W2016343650 @default.
• W2897943350 cites W2034017747 @default.
• W2897943350 cites W2036311740 @default.
• W2897943350 cites W2045203690 @default.
• W2897943350 cites W2045712356 @default.
• W2897943350 cites W2054385054 @default.
• W2897943350 cites W2060760531 @default.
• W2897943350 cites W2066343477 @default.
• W2897943350 cites W2072355125 @default.
• W2897943350 cites W2076233644 @default.
• W2897943350 cites W2112345476 @default.
• W2897943350 cites W2158757628 @default.
• W2897943350 cites W2159020660 @default.
• W2897943350 cites W2215044613 @default.
• W2897943350 cites W2333203867 @default.
• W2897943350 cites W2416119553 @default.
• W2897943350 cites W2424155007 @default.
• W2897943350 cites W2602440856 @default.
• W2897943350 cites W2746840706 @default.
• W2897943350 cites W2751449029 @default.
• W2897943350 cites W2755663477 @default.
• W2897943350 cites W2755733485 @default.
• W2897943350 cites W2766372609 @default.
• W2897943350 cites W2796712246 @default.
• W2897943350 cites W2799601627 @default.
• W2897943350 cites W2873595960 @default.
• W2897943350 cites W2883475083 @default.
• W2897943350 doi "https://doi.org/10.21037/tlcr.2018.10.04" @default.
• W2897943350 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6204422" @default.
• W2897943350 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30450291" @default.
• W2897943350 hasPublicationYear "2018" @default.
• W2897943350 type Work @default.
• W2897943350 sameAs 2897943350 @default.
• W2897943350 citedByCount "53" @default.
• W2897943350 countsByYear W28979433502019 @default.
• W2897943350 countsByYear W28979433502020 @default.
• W2897943350 countsByYear W28979433502021 @default.
• W2897943350 countsByYear W28979433502022 @default.
• W2897943350 countsByYear W28979433502023 @default.
• W2897943350 crossrefType "journal-article" @default.
• W2897943350 hasAuthorship W2897943350A5048441847 @default.
• W2897943350 hasAuthorship W2897943350A5056727791 @default.
• W2897943350 hasBestOaLocation W28979433502 @default.
• W2897943350 hasConcept C126322002 @default.
• W2897943350 hasConcept C126838900 @default.
• W2897943350 hasConcept C142724271 @default.
• W2897943350 hasConcept C143998085 @default.
• W2897943350 hasConcept C204232928 @default.
• W2897943350 hasConcept C2776694085 @default.
• W2897943350 hasConcept C2777240266 @default.
• W2897943350 hasConcept C2777407522 @default.
• W2897943350 hasConcept C2778239845 @default.
• W2897943350 hasConcept C2778995398 @default.
• W2897943350 hasConcept C2779399171 @default.
• W2897943350 hasConcept C2781404787 @default.
• W2897943350 hasConcept C37846818 @default.
• W2897943350 hasConcept C71924100 @default.
• W2897943350 hasConceptScore W2897943350C126322002 @default.
• W2897943350 hasConceptScore W2897943350C126838900 @default.
• W2897943350 hasConceptScore W2897943350C142724271 @default.
• W2897943350 hasConceptScore W2897943350C143998085 @default.
• W2897943350 hasConceptScore W2897943350C204232928 @default.
• W2897943350 hasConceptScore W2897943350C2776694085 @default.
• W2897943350 hasConceptScore W2897943350C2777240266 @default.
• W2897943350 hasConceptScore W2897943350C2777407522 @default.
• W2897943350 hasConceptScore W2897943350C2778239845 @default.
• W2897943350 hasConceptScore W2897943350C2778995398 @default.
• W2897943350 hasConceptScore W2897943350C2779399171 @default.
• W2897943350 hasConceptScore W2897943350C2781404787 @default.
• W2897943350 hasConceptScore W2897943350C37846818 @default.
• W2897943350 hasConceptScore W2897943350C71924100 @default.
• W2897943350 hasIssue "5" @default.
• W2897943350 hasLocation W28979433501 @default.
• W2897943350 hasLocation W28979433502 @default.
• W2897943350 hasLocation W28979433503 @default.
• W2897943350 hasLocation W28979433504 @default.
• W2897943350 hasOpenAccess W2897943350 @default.
• W2897943350 hasPrimaryLocation W28979433501 @default.
• W2897943350 hasRelatedWork W1993319780 @default.
• W2897943350 hasRelatedWork W2168841084 @default.
• W2897943350 hasRelatedWork W2465982491 @default.
• W2897943350 hasRelatedWork W2897902564 @default.
• W2897943350 hasRelatedWork W2897943350 @default.
• W2897943350 hasRelatedWork W2938922501 @default.
• W2897943350 hasRelatedWork W3007471128 @default.
• W2897943350 hasRelatedWork W3042471957 @default.
• W2897943350 hasRelatedWork W4232465298 @default.

• next